Study links three pesticides to non-Hodgkin's lymphoma

Dutch researchers have published the results of a prospective study that they believe links the exposure of certain pesticides to the development of non-Hodgkin's lymphoma (NHL).

The study, published in the journal Environmental Health Perspectives, involved the collection of fat tissue samples from a large cohort of over 57,000 Danish men and women in their 50s and 60s between the years 1993 and 1997.

Since toxins tend to collect in fat tissue, those samples were analyzed for eight pesticides and ten polychlorinated biphenyl congeners (PCBs).

Researchers could find no association between PCB exposure and NHL.

However, they did find an association between the exposure of three pesticides and the development of NHL later in life:

- DDT
- cis-nonachlor
- Oxychlordane

The association was determined to be slightly stronger in men than in women, and there was no association found with body-mass index.

Although none of these pesticides are in use any longer in the United States, they remain in the environment.

Source

Bräuner EV et al. A prospective study of organochlorines in adipose tissue and risk of non-Hodgkin’s Lymphoma. Environ Health Perspect :-. http://dx.doi.org/10.1289/ehp.1103573

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap